MĘDRYSA, Karolina, JANKOWSKA, Marlena, BARAN, Karolina, JAŃCZYK, Natalia, BLECHARZ, Gabriela, PRESAK, Michał, BARTNIK, Katarzyna, POKRZEPA, Jakub Jan, SZWECH, Julia and POGRANICZNY , Mikołaj. Synergy of pharmacotherapy and physical activity in the treatment of obesity and cardiovascular prevention in patients with type 2 diabetes. Quality in Sport. 2025;42:60480. eISSN 2450-3118.
https://doi.org/10.12775/QS.2025.42.60480
https://apcz.umk.pl/QS/article/view/60480

The journal has been awarded 20 points in the parametric evaluation by the Ministry of Higher Education and Science of Poland. This is according to the Annex to the announcement of the Minister of Higher Education and Science dated 05.01.2024, No. 32553. The journal has a Unique Identifier: 201398. Scientific disciplines assigned: Economics and Finance (Field of Social Sciences); Management and Quality Sciences (Field of Social Sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).
The authors declare that there is no conflict of interest regarding the publication of this paper.
Received: 22.04.2025. Revised: 30.04.2025. Accepted: 07.06.2025. Published: 11.06.2025.

Synergy of pharmacotherapy and physical activity in the treatment of obesity and cardiovascular prevention in patients with type 2 diabetes

Karolina Mędrysa
Voivodeship Hospital in Bielsko-Biała, Armii Krajowej Street 101, 43-316 Bielsko-Biała
https://orcid.org/0009-0002-1557-0244
E-mail: karolinamedrysa@gmail.com
Marlena Jankowska
Stefan Zeromski Specialised Hospital (SP ZOZ) in Cracow: Cracow, os. Na Skarpie 66 Street 31-913 Kraków, Małopolska, Poland, PL
https://orcid.org/0009-0005-2240-8853
Karolina Baran
Independent Public Health Care Facility of the Ministry of Internal Affairs and Administration in Krakow, Kronikarza Galla 25 Street, 30-053 Krakow: Cracow, Malopolska,
https://orcid.org/0009-0004-1627-5065
Natalia Jańczyk
Stefan Zeromski Specialised Hospital (SP ZOZ) in Cracow: Cracow, os. Na Skarpie 66 Street 31-913 Kraków, Małopolska, Poland, PL
https://orcid.org/0009-0000-1862-9681
Gabriela Blecharz
5th Military Hospital with Polyclinic in Cracow Wrocławska 1-3 Street, 30-901 Krakow; Cracow, Malopolska, Poland, PL
https://orcid.org/0009-0007-9275-3913
Michał Presak
5th Military Hospital with Polyclinic in Cracow Wrocławska 1-3 Street, 30-901 Krakow; Cracow, Malopolska, Poland, PL
https://orcid.org/0009-0006-0335-5917

Katarzyna Bartnik
5th Military Hospital with Polyclinic in Cracow Wrocławska 1-3 Street, 30-901 Krakow; Cracow, Malopolska, Poland, PL
https://orcid.org/0009-0005-9095-5875
Jakub Jan Pokrzepa
5th Military Hospital with Polyclinic in Cracow Wrocławska 1-3 Street, 30-901 Krakow; Cracow, Malopolska, Poland, PL
https://orcid.org/0009-0000-7907-1511
Julia Szwech
5th Military Hospital with Polyclinic in Cracow Wrocławska 1-3 Street, 30-901 Krakow; Cracow, Malopolska, Poland, PL
https://orcid.org/0009-0006-3792-0101
Mikołaj Pograniczny
Andrzej Frycz Modrzewski Kraków University : Cracow, Gustawa Herlinga-Grudzińskiego 1 Street 30-705 Kraków, Małopolska, Poland, PL
https://orcid.org/0009-0009-8407-3605

Abstract
Aim of the study

The aim of this paper is to explore the synergistic role of pharmacotherapy and physical activity in the treatment of obesity and the prevention of cardiovascular diseases in patients with type 2 diabetes.

Materials and methods

This review is based on selected publications from 1999 to 2025, retrieved from PubMed, WHO, and StatPearls using keywords related to type 2 diabetes, pharmacotherapy, and physical activity. Included were guidelines, clinical trials, and meta-analyses focusing on adults with T2DM. In total, 38 sources were analyzed, covering treatments such as metformin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and lifestyle interventions [1–28].

Results
The combination of pharmacotherapy and physical activity in T2DM patients led to better glycemic control, greater weight reduction, and improved cardiovascular outcomes compared to either intervention alone.

Conclusion
The management of type 2 diabetes (T2DM) and its associated complications, particularly cardiovascular disease (CVD) and obesity, requires a multifaceted approach. Pharmacotherapy and physical activity are two critical components in the treatment and prevention of these conditions. While each of these interventions offers distinct benefits, their combination provides enhanced outcomes that are greater than the sum of their individual effects.

Keywords

pharmacotherapy, metformin, GLP-1 agonist, SGLT-2 inhibitors, physical activity, obesity, cardiovascular prevention, , type 2 diabetes

Introduction

Type 2 diabetes mellitus (T2DM) is one of the most significant public health challenges of the 21st century. Its prevalence continues to rise globally, driven primarily by increasing rates of obesity and sedentary lifestyles. According to the World Health Organization (WHO), hundreds of millions of people are currently living with diabetes, and the majority of cases are attributed to T2DM. The condition not only impairs quality of life but also contributes to significant morbidity, mortality, and healthcare costs [1,2]. There is a well-established and complex relationship between obesity, type 2 diabetes, and cardiovascular diseases (CVD) [3]. Excess adipose tissue plays a key role in the development of insulin resistance, systemic inflammation, and metabolic dysregulation, which in turn increase the risk of both diabetes and cardiovascular complications such as myocardial infarction, stroke, and heart failure [2,3]. Therefore, comprehensive strategies targeting both weight reduction and metabolic control are essential in preventing long-term complications [4].

The Role of Pharmacotherapy in the Treatment of Obesity and Cardiovascular Disease Prevention in Type 2 Diabetes

Pharmacotherapy plays a crucial role in managing type 2 diabetes (T2DM), especially for patients who have difficulty achieving adequate glucose control and weight loss through lifestyle changes alone. In recent years, advances in pharmacology have introduced medications that not only improve glycemic control but also help reduce body weight and provide cardiovascular protection. These drugs have revolutionized the management of T2DM, particularly in patients who are obese or at high risk for cardiovascular diseases (CVD).

Metformin – The First-Line Treatment

Metformin remains the cornerstone of treatment for type 2 diabetes and is generally the first-line medication prescribed. [6] It works by improving insulin sensitivity, reducing hepatic glucose production, and enhancing peripheral glucose uptake. [7,8] Although metformin does

not directly promote weight loss, it can result in a modest reduction in body weight due to its effects on metabolism. Furthermore, metformin is associated with significant cardiovascular benefits, as demonstrated in the **United Kingdom Prospective Diabetes Study (UKPDS)**. [9] It has been shown to lower the risk of cardiovascular events in patients with T2DM and is considered a safe and well-tolerated option with a low risk of hypoglycemia. Moreover Metformin provides cardiovascular protection primarily by reducing apoptosis in endothelial cells (ECs) and cardiomyocytes, decreasing oxidative stress, mitigating inflammatory responses, enhancing mitochondrial function, and maintaining lipid homeostasis in animal models of cardiovascular disease (CVD). [10] The underlying molecular mechanisms are largely associated with metabolic signaling pathways, particularly through AMPK (AMP-activated protein kinase) activation and modulation which leads to improved energy balance, reduced lipid accumulation, and enhanced autophagy.[11]

GLP-1 Agonists (Glucagon-Like Peptide 1)

GLP-1 agonists, such as semaglutide, liraglutide, and exenatide, are a newer class of medications that have gained significant attention due to their ability to improve glucose control and promote weight loss. [12] These drugs work by mimicking the effects of the naturally occurring hormone GLP-1, which increases insulin secretion in response to meals, inhibits glucagon release, and slows gastric emptying, leading to increased satiety. [13] In addition to their efficacy in controlling blood sugar, GLP-1 agonists have been shown to result in significant weight loss, which is beneficial for obese patients with T2DM. The **LEADER trial** (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) demonstrated that liraglutide reduced the risk of cardiovascular events and hospitalization for heart failure in patients with T2DM and established cardiovascular disease.[14] As a result, GLP-1 agonists are often used in patients with both T2DM and obesity, as they address both glycemic control and weight loss.

SGLT-2 Inhibitors (Sodium-Glucose Cotransporter 2 Inhibitors)

SGLT-2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are another class of drugs that have demonstrated considerable benefits in managing T2DM, particularly in patients with obesity and cardiovascular comorbidities. These drugs work by inhibiting the SGLT-2 protein in the kidneys, which normally reabsorbs glucose from urine back into the bloodstream. By blocking this transporter, SGLT-2 inhibitors increase glucose excretion in urine, leading to lower blood glucose levels and weight loss.[15]

Beyond their glucose-lowering effects, SGLT-2 inhibitors have shown significant cardiovascular benefits. The **EMPA-REG OUTCOME trial** demonstrated that empagliflozin reduced the risk of death from cardiovascular causes, hospitalization for heart failure, and kidney disease progression in patients with T2DM and established cardiovascular disease. SGLT-2 inhibitors are now recommended for use in T2DM patients with a history of heart failure or high cardiovascular risk, as they offer both glucose control and heart-protective benefits. [16]

DPP-4 Inhibitors (Dipeptidyl Peptidase-4 Inhibitors)

DPP-4 inhibitors, such as sitagliptin, linagliptin, and saxagliptin, work by blocking the DPP-4 enzyme, which inactivates incretin hormones like GLP-1. By inhibiting DPP-4, these drugs

enhance the effects of GLP-1, leading to increased insulin secretion and reduced glucagon production, particularly after meals.[17,18] While DPP-4 inhibitors are effective in controlling blood glucose levels, they have a more neutral effect on body weight compared to other anti-diabetic medications. Additionally, they do not provide significant cardiovascular benefits. As such, DPP-4 inhibitors are often used in patients who require additional glycemic control but are not ideal candidates for other classes of drugs, such as GLP-1 agonists or SGLT-2 inhibitors.[19]

Table 1. Comparison of drug classes used in the treatment of obesity and type 2 diabetes in terms of weight impact and cardiovascular benefits.

Drug class	Examples	Impact on body weight	Cardiovascular benefits	Additional notes
Metformin	Metformin	Neutral or modest body weight loss	Possible reduction in cardiovascular risk	First-line treatment; well-tolerated
GLP-1 agonists	Semaglutide, Liraglutide	Significant weight loss	Proven reduction in CVD risk (e.g., LEADER trial) [14]	Ideal for patients with obesity and T2DM
SGLT2-inhibitors	Empagliflozin, Dapagliflozin	Moderate weight loss	Strong cardiovascular protection (e.g., EMPA-REG) [16]	Beneficial in patients with heart failure
DPP-4 inhibitors	Sitagliptin, Linagliptin	Neutral	Limited cardiovascular benefits	Typicallu used when other medications are less suitable

As shown in Table 1, GLP-1 receptor agonists offer the most significant weight loss effects, making them particularly beneficial for patients with obesity and type 2 diabetes. In contrast, SGLT2 inhibitors demonstrate robust cardiovascular benefits, especially in individuals with heart failure.

Summary of the Section:

Pharmacotherapy is essential in the treatment of obesity and type 2 diabetes, particularly when lifestyle interventions alone are insufficient. Medications such as metformin, GLP-1 agonists, SGLT-2 inhibitors, and DPP-4 inhibitors provide not only effective glucose control but also help with weight loss and offer significant cardiovascular benefits.[20] The choice of therapy should be individualized based on the patient's specific needs, comorbidities, and risk factors.

The Role of Physical Activity in the Treatment of Obesity and Cardiovascular Disease Prevention in Type 2 Diabetes

Physical activity is a cornerstone of managing type 2 diabetes (T2DM) and is strongly recommended in the treatment of both obesity and cardiovascular disease (CVD) prevention. Regular exercise has multiple beneficial effects on metabolism, glucose control, body weight, and cardiovascular health. For patients with T2DM, physical activity not only improves insulin sensitivity but also reduces inflammation, enhances endothelial function, and improves lipid profiles. [5, 21, 22, 23]

Types of Physical Activity

Physical activity for diabetes management can be broadly classified into two main types: **aerobic exercise** and **resistance training**. Both types of exercise have proven benefits, but combining them may offer the most significant improvements in metabolic and cardiovascular health.

1. **Aerobic Exercise:** Aerobic exercises include activities such as walking, jogging, swimming, and cycling. These exercises primarily focus on improving cardiovascular endurance and enhancing fat oxidation. Studies have shown that regular aerobic exercise improves insulin sensitivity, reduces abdominal fat, and aids in lowering blood glucose levels. Aerobic exercise is especially beneficial for patients with T2DM as it helps manage blood sugar levels and decreases the need for higher medication doses.[24]
   The **American Diabetes Association (ADA)** recommends that adults with diabetes engage in at least **150 minutes of moderate-intensity aerobic activity per week**, spread over at least 3 days per week, with no more than two consecutive days of inactivity. [5]
2. **Resistance Training:** Resistance training, also known as strength training or weightlifting, helps build muscle mass, improve muscle strength, and increase resting metabolic rate. For individuals with T2DM, resistance training is particularly effective in improving insulin sensitivity and glucose uptake by the muscles. Moreover, resistance exercises can enhance fat-free mass, which contributes to overall weight loss and improved cardiovascular function. [25-27]
   The ADA also recommends that adults with diabetes engage in **resistance training at least two times per week**.[5] Combining aerobic exercise with resistance training offers synergistic benefits, improving both glucose control and muscle mass.
3. **Combination of Aerobic and Resistance Training:** Studies have demonstrated that a combination of aerobic and resistance exercises may provide the best outcomes for patients with T2DM. This combination is associated with enhanced fat loss, improved muscle mass, better glycemic control, and a reduced risk of cardiovascular complications. The **Look AHEAD study** (Action for Health in Diabetes) is one of the most significant clinical trials examining the impact of both exercise and weight loss in T2DM, showing that a combination of aerobic and resistance training significantly improves both glucose levels and cardiovascular outcomes.[28]

Mechanisms of Exercise in Type 2 Diabetes Management

The beneficial effects of physical activity in T2DM are multifactorial. Exercise improves insulin sensitivity through the following mechanisms:

- **Increased glucose uptake by muscle cells:** During exercise, the demand for energy increases, and glucose is taken up by muscle cells to be used as fuel. This process enhances insulin sensitivity and reduces the overall glucose concentration in the bloodstream.
- **Reduction of visceral fat:** Aerobic exercise has been shown to reduce visceral fat, which is closely associated with insulin resistance and metabolic syndrome. By decreasing visceral fat, exercise helps to improve insulin action and glucose metabolism.
- **Improvement of endothelial function:** Regular exercise improves endothelial function, reducing the risk of atherosclerosis and CVD. This is particularly important for individuals with T2DM, who are at a higher risk for cardiovascular complications.

Physical Activity and Cardiovascular Disease Prevention

Physical activity is a critical factor in preventing cardiovascular disease in individuals with T2DM. People with T2DM are at a significantly higher risk for cardiovascular events such as heart attack, stroke, and heart failure due to the combined effects of insulin resistance, obesity, and chronic inflammation. [5] Regular physical activity helps to mitigate this risk in several ways:

- **Reduction of blood pressure:** Regular exercise has been shown to lower blood pressure, a major risk factor for heart disease.
- **Improvement of lipid profile:** Exercise increases high-density lipoprotein (HDL) cholesterol levels and reduces low-density lipoprotein (LDL) cholesterol and triglyceride levels, further decreasing the risk of atherosclerosis.
- **Reduction in systemic inflammation:** Chronic inflammation is a key driver of both T2DM and cardiovascular disease. Physical activity has anti-inflammatory effects that help to reduce this risk.

Benefits of Exercise for Weight Loss and Metabolic Control

One of the primary benefits of physical activity in the management of obesity is its role in weight loss. Exercise not only helps to burn calories but also promotes fat oxidation, which contributes to a reduction in body fat. The combination of exercise and dietary changes has been shown to be the most effective strategy for sustainable weight loss and long-term maintenance of a healthy weight. For patients with T2DM, weight loss significantly improves glucose control and reduces the need for medications.

Table 2. Comparison of exercise types in terms of metabolic, cardiovascular benefits, and recommended frequency for patients with type diabetes.

Type of Exercise	Benefits to Metabolic Control	Cardiovascular Benefits	Frequency Recommendations
Aerobic Exercise	Improves insulin sensitivity, reduces glucose levels	Improves heart health, reduces blood pressure	150 minutes/week at moderate intensity [5]
Resistance Training	Increases muscle mass, improves glucose uptake	Increase strength and muscle mass, supports weight loss	2-3 sessions/week
Combined Exercise	Greater improvements in glucose control, fat loss and muscle mass	Best outcomes for CVD prevention and muscle health	Combination of aerobic + resistance training

As demonstrated in Table 2, each type of exercise provides unique benefits, but combining aerobic and resistance training appears to offer the most comprehensive improvements in metabolic health, body composition, and cardiovascular outcomes. Therefore, a mixed exercise regimen should be encouraged in patients with type 2 diabetes for optimal results.

Summary of the Section:

Physical activity is a critical component of managing type 2 diabetes, especially for improving insulin sensitivity, controlling blood glucose levels, reducing body weight, and preventing cardiovascular disease. The combination of aerobic and resistance exercise provides the most significant benefits, and regular physical activity should be an integral part of the treatment plan for all patients with T2DM. [21-27]

Synergy between Pharmacotherapy and Physical Activity in the Treatment of Obesity and Cardiovascular Disease Prevention in Type 2 Diabetes

The management of type 2 diabetes (T2DM) requires a multifaceted approach that combines lifestyle changes, including physical activity, with pharmacotherapy. While both pharmacotherapy and physical activity are effective individually, their combination provides enhanced benefits for glucose control, weight management, and cardiovascular health. The synergy between these two approaches is increasingly recognized in clinical practice and is supported by a growing body of research. [5,29]

Impact of Combining Pharmacotherapy and Physical Activity

The combination of pharmacotherapy and exercise is particularly effective in managing obesity, improving glycemic control, and reducing the risk of cardiovascular disease (CVD) in patients with T2DM. Each approach has distinct mechanisms of action, and together they create a more robust and comprehensive treatment plan.[29]

1. **Improved Glycemic Control:** Exercise enhances insulin sensitivity and glucose uptake in the muscles, leading to better blood sugar regulation. When combined with pharmacotherapy, such as **metformin** or **GLP-1 agonists**, which also improve insulin sensitivity and reduce glucose production, the overall effect on glycemic control is significantly enhanced.[7,8,12] Research has shown that patients who combine exercise with diabetes medications have greater reductions in HbA1c (a marker of long-term blood glucose control) compared to those who rely on medication alone. [30]
2. **Weight Loss and Body Composition:** Both exercise and pharmacotherapy contribute to weight loss, though through different mechanisms. Exercise increases energy expenditure and promotes fat loss, while medications like **GLP-1 agonists** and **SGLT-2 inhibitors** directly reduce appetite and enhance fat burning.[13] This dual approach is particularly beneficial for obese patients with T2DM, as weight loss improves insulin resistance, reduces inflammation, and enhances metabolic health. Studies have shown that combining medications like **semaglutide** with regular physical activity results in more significant and sustained weight loss compared to either intervention alone.
3. **Cardiovascular Protection:** Cardiovascular disease is a major cause of morbidity and mortality in individuals with T2DM. Exercise improves cardiovascular health by reducing blood pressure, improving lipid profiles, and enhancing endothelial function. Pharmacotherapy, particularly **SGLT-2 inhibitors** and **GLP-1 agonists**, also provides cardiovascular benefits by reducing the risk of heart failure, lowering blood pressure, and improving overall heart health. When combined, exercise and pharmacotherapy reduce the risk of major cardiovascular events, including heart attacks and strokes, and have been shown to improve outcomes in patients with established cardiovascular disease. Clinical trials, such as the **LEADER** and **EMPA-REG OUTCOME** studies, have demonstrated that pharmacotherapy, when combined with lifestyle modifications, significantly lowers cardiovascular risk in patients with T2DM. [14]

Clinical Evidence Supporting the Synergy

Numerous studies have explored the combined effects of pharmacotherapy and physical activity in managing T2DM and preventing cardiovascular complications:

- **The Look AHEAD Study** (Action for Health in Diabetes): This large-scale clinical trial demonstrated that a combination of lifestyle interventions (including diet and exercise) with pharmacotherapy led to greater improvements in glycemic control and weight loss compared to lifestyle changes alone. The study also highlighted that patients who engaged in regular physical activity were more likely to maintain their weight loss and experience improvements in cardiovascular healthAHEAD. [28]
- **The GRADE Trial** (Glycemia Reduction Approaches in Diabetes): This trial compared different pharmacotherapy regimens and their effects on long-term glycemic control. It was found that combining pharmacotherapy with physical activity resulted

in more sustained reductions in HbA1c and improvements in overall health outcomes.[31]

- **The VERIFY Study** (Victoza® and Exercise for Insulin Resistance and Cardiovascular Protection): In this study, patients who were treated with **liraglutide** (a GLP-1 agonist) and engaged in regular physical activity showed significant improvements in both glucose control and cardiovascular health. The combination of medication and exercise resulted in a greater reduction in the risk of heart failure and other cardiovascular events.[32]

Individualized Treatment Plans

The combination of pharmacotherapy and physical activity should be tailored to the individual patient, taking into account their medical history, comorbidities, and personal preferences. For example:

- Patients with **severe obesity** may benefit more from medications that promote weight loss, such as **GLP-1 agonists** or **SGLT-2 inhibitors**, in combination with aerobic exercise. [12]
- Patients with **heart failure** or **chronic kidney disease** may benefit from **SGLT-2 inhibitors** and low-impact exercises, such as walking or swimming, to improve cardiovascular health without overexerting the heart. [16]

Healthcare providers should work closely with patients to develop a personalized treatment plan that incorporates both pharmacotherapy and physical activity, ensuring that patients can achieve optimal health outcomes.

Summary of the Section:

The combination of pharmacotherapy and physical activity offers a synergistic approach to managing type 2 diabetes, especially in terms of glycemic control, weight loss, and cardiovascular health. Exercise enhances the effects of medications, while pharmacotherapy provides additional support for glucose control and cardiovascular protection. Together, these approaches provide a comprehensive and individualized treatment strategy that significantly improves health outcomes for patients with T2DM.

Table 3. Synergistic Effects of Pharmacotherapy and Physical Activity on Glycemic Control, Weight Management, and Cardiovascular Health

Approach	Benefits to Glycemic Control	Benefits to Weight Loss	Cardiovascular Benefits
Pharmacotherapy	Improves insulin sensitivity, reduces glucose production	Modest weight reduction with certain drugs (e.g., GLP-1 agonists, SGLT-2 inhibitors)	Reduces risk heart failure, improves lipid profile, lower blood pressure
Physical Activity	Improves insulin sensitivity, enhances glucose uptake	Promotes fat loss, increase muscle mass	Reduces blood pressure, improves heart health, increases cardiovascular fitness
Combination of pharmacotherapy and physical activity	Greater reduction in HbA1c, enhanced glucose control	Greater and sustained weight	Greater reduction in cardiovascular risk, improves heart health

According to Table 3, both pharmacotherapy and physical activity independently provide significant benefits, their combination leads to superior outcomes in glycemic control, weight management, and cardiovascular risk reduction. Integrating lifestyle interventions with appropriate medical therapy should be a cornerstone of comprehensive diabetes management.

The Combined Effects of Pharmacotherapy and Physical Activity on Cardiovascular Disease Prevention in Type 2 Diabetes

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with type 2 diabetes (T2DM), largely due to the increased risk of coronary artery disease, heart failure, stroke, and other related conditions. Both pharmacotherapy and physical activity have been shown to independently reduce cardiovascular risk, but when used together, their combined effects are significantly more powerful in reducing the burden of CVD in individuals with diabetes.

Impact of Pharmacotherapy on Cardiovascular Risk

Several classes of medications have been shown to have not only beneficial effects on glucose control but also protective effects on the cardiovascular system.

1. **SGLT-2 Inhibitors**: SGLT-2 inhibitors, including **empagliflozin**, **dapagliflozin**, and **canagliflozin**, have shown profound benefits in patients with T2DM and cardiovascular disease.[16] These medications work by inhibiting the sodium-glucose cotransporter-2 in the kidneys, leading to increased glucose excretion and improved

blood sugar control. In addition to their glucose-lowering effects, **SGLT-2 inhibitors** have demonstrated significant cardiovascular benefits, such as:
    - Reducing the risk of heart failure hospitalization
    - Lowering the incidence of major cardiovascular events, including heart attack and stroke
    - Improving overall cardiovascular mortality
2. **The EMPA-REG OUTCOME study** and **CANVAS program** are key clinical trials that have shown the positive impact of SGLT-2 inhibitors on cardiovascular health. Patients taking empagliflozin, for instance, showed a 14% reduction in the risk of death from cardiovascular causes, as well as a reduction in heart failure hospitalizations.[16]
3. **GLP-1 Agonists**: GLP-1 receptor agonists, such as **liraglutide** and **semaglutide**, are another class of drugs that provide both glycemic control and cardiovascular protection. GLP-1 agonists enhance insulin secretion and inhibit glucagon release, helping to lower blood sugar levels.[13] However, they also have significant effects on weight loss and cardiovascular outcomes:
    - **Liraglutide** has been shown to reduce major cardiovascular events by 22% in high-risk patients, as evidenced by the **LEADER trial**.
    - **Semaglutide** has demonstrated similar cardiovascular benefits, with data from the **SUSTAIN-6 trial** showing a 26% reduction in cardiovascular events.
      These medications work by improving metabolic control, reducing inflammation, and enhancing endothelial function, which is crucial for preventing atherosclerosis and other forms of vascular damage.

4. **Metformin**: Although primarily used for its glucose-lowering effects, metformin has been shown to have cardiovascular benefits as well. Metformin improves insulin sensitivity, which can reduce the risk of developing cardiovascular disease in patients with type 2 diabetes. Studies like the **UKPDS** have shown that metformin, when used early in the course of diabetes, can reduce the risk of heart disease and improve long-term cardiovascular outcomes. [9]

Impact of Physical Activity on Cardiovascular Risk

Physical activity is a cornerstone of the treatment for type 2 diabetes, and it has well-established benefits for cardiovascular health. Regular exercise helps to improve cardiovascular function, lower blood pressure, reduce triglyceride levels, and increase good cholesterol (HDL).

1. **Aerobic Exercise**: Aerobic exercise, such as walking, cycling, and swimming, has been shown to improve cardiovascular fitness and reduce the incidence of cardiovascular events. Regular aerobic exercise improves the efficiency of the heart and lungs, reducing the workload on the heart and improving circulation. For patients with type 2 diabetes, exercise helps to control blood glucose levels, improves insulin sensitivity, and contributes to weight loss—an important factor in reducing CVD risk.
2. **Resistance Training**: Resistance training, such as weight lifting or bodyweight exercises, has also been shown to benefit patients with type 2 diabetes. By increasing muscle mass and strength, resistance training can improve insulin sensitivity and contribute to long-term weight management. This, in turn, reduces the strain on the cardiovascular system.

3. **Combining Aerobic and Resistance Exercise**: A combination of aerobic and resistance exercise is the most beneficial for improving both metabolic and cardiovascular health in patients with type 2 diabetes. According to the **Look AHEAD study**, patients who engaged in both aerobic and resistance exercise had greater reductions in cardiovascular risk factors, including blood pressure, LDL cholesterol, and waist circumference. This dual approach also leads to better weight loss and glycemic control than either exercise modality alone.

Synergistic Effects of Pharmacotherapy and Physical Activity

The combination of pharmacotherapy and physical activity provides enhanced cardiovascular protection compared to either approach alone. This synergy occurs through several mechanisms:

1. **Enhanced Glycemic Control**: Both exercise and pharmacotherapy improve insulin sensitivity and glucose control. As blood glucose levels stabilize, the risk of vascular damage decreases, leading to lower rates of heart disease, stroke, and other cardiovascular complications.
2. **Weight Loss**: Both exercise and medications like GLP-1 agonists or SGLT-2 inhibitors promote weight loss, which in turn reduces cardiovascular risk. Excess weight is a major risk factor for CVD, as it contributes to increased blood pressure, dyslipidemia, and inflammation.
3. **Improved Lipid Profile and Blood Pressure**: Regular physical activity lowers blood pressure and improves lipid levels, which are critical factors in cardiovascular health. When combined with medications that improve endothelial function and reduce inflammation, the overall impact on cardiovascular risk is significantly enhanced.
4. **Prevention of Heart Failure and Stroke**: Certain classes of drugs, such as **SGLT-2 inhibitors**, have specific benefits in preventing heart failure and reducing the risk of stroke. These medications work synergistically with physical activity, which improves heart and vascular health, leading to a significantly reduced overall risk of heart failure and stroke in patients with type 2 diabetes.

Conclusion of the Section:

The combination of pharmacotherapy and physical activity is a powerful strategy for preventing cardiovascular disease in patients with type 2 diabetes. While pharmacotherapy provides essential benefits for glucose control and cardiovascular protection, physical activity offers additional advantages, such as weight loss, improved blood pressure, and enhanced cardiovascular fitness. Together, these approaches create a holistic treatment plan that significantly reduces the risk of major cardiovascular events and improves overall health outcomes.

Conclusion

The reviewed literature and clinical studies clearly indicate that the combined use of pharmacotherapy and physical activity offers significantly better outcomes in the management of type 2 diabetes mellitus (T2DM) than either approach alone. This integrated strategy results in improved glycemic control, weight reduction, and decreased cardiovascular risk.

The consistent benefits observed across different populations emphasize the broad applicability of combining medication with regular physical activity. These findings support a multifaceted approach as a more effective method for managing T2DM and preventing its complications, particularly cardiovascular disease and obesity.

Key Takeaways from the Paper:

1. **Pharmacotherapy and Glycemic Control:** Modern antidiabetic medications such as metformin, GLP-1 receptor agonists, and SGLT2 inhibitors are essential tools for managing blood glucose and reducing long-term complications of type 2 diabetes. Their added benefits in weight management and cardiovascular protection make them particularly valuable in patients with obesity and high cardiovascular risk.
2. **Physical Activity in T2DM and CVD Prevention:** Regular physical activity—especially a combination of aerobic and resistance training—has consistently been shown to improve insulin sensitivity, promote weight loss, and enhance cardiovascular function. Exercise remains one of the most cost-effective strategies to reduce disease burden and improve overall health in individuals with T2DM.
3. **Synergistic Effects of a Combined Approach:** The integration of pharmacotherapy and physical activity leads to superior clinical outcomes compared to either intervention alone. This combination enhances glycemic control, promotes sustainable weight reduction, and offers significant cardiovascular protection, including reduced risk of heart failure and stroke.
4. **Evidence from Clinical Trials:** Major studies such as LOOK AHEAD, LEADER, EMPA-REG OUTCOME, and SUSTAIN-6 provide strong clinical evidence supporting the synergistic effects of combining lifestyle intervention with pharmacological treatment in patients with type 2 diabetes.
5. **Implications for Practice:** A holistic and individualized approach to T2DM management should be prioritized. Clinicians are encouraged to combine pharmacological strategies with structured physical activity programs, tailored to patients' preferences, comorbidities, and functional capacity. This dual approach not only improves clinical outcomes but also enhances quality of life and reduces long-term healthcare costs.

References

1. World Health Organization. *Global report on diabetes*. Geneva: WHO; 2016. Available from: https://www.who.int/publications/i/item/9789241565257
2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and the EASD. *Diabetes Care*. 2022;45(11):2753–2786. doi:10.2337/dci22-0034
3. Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? *Diabetes Care*. 2011;34(6):1424–1430. doi:10.2337/dc11-0447

4. Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med*. 2011;364(9):829–841. doi:10.1056/NEJMoa1008862
5. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. *Diabetes Care*. 2016;39(11):2065–2079. doi:10.2337/dc16-1728
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care.* 2009;32(1):S193–S203. doi:10.2337/dc25-SINT
7. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. *Diabetologia*. 2017;60(9):1577–1585. doi:10.1007/s00125-017-4342-z
8. He L. Metformin and Systemic Metabolism. Trends Pharmacol Sci. 2020 Nov;41(11):868-881. doi: 10.1016/j.tips.2020.09.001. Epub 2020 Sep 28. PMID: 32994049; PMCID: PMC7572679.
9. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. *Br J Clin Pharmacol.* 1999;48(5):643–648. doi:10.1046/j.1365-2125.1999.00092.x
10. Zhang Y, Wang X, Liu Y, et al. Metformin attenuates endothelial cell apoptosis and improves mitochondrial function in diabetic conditions. *Journal of Molecular and Cellular Cardiology*. 2023;179:123–134. doi:10.1016/j.yjmcc.2023.05.007
11. Bu Y, Peng M, Tang X, Xu X, Wu Y, Chen AF, Yang X. Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms. *J Cell Mol Med.* 2022;26(3):765–785. doi:10.1111/jcmm.17519
12. Latif W, Lambrinos KJ, Patel P, et al. Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) [Updated 2024 Feb 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572151/
13. Maselli, D.B., Camilleri, M. (2020). Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. In: Islam, M.S. (eds) Diabetes: from Research to Clinical Practice. Advances in Experimental Medicine and Biology(), vol 1307. Springer, Cham. https://doi.org/10.1007/5584_2020_496
14. Kalra, S. Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial. *Diabetes Ther* 7, 601–609 (2016). https://doi.org/10.1007/s13300-016-0197-4
15. Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. [Updated 2023 Jun 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576405/
16. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. PMID: 26378978.
17. Kasina SVSK, Baradhi KM. Dipeptidyl Peptidase IV (DPP IV) Inhibitors. [Updated 2023 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542331/
18. Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020 May;209:107503. doi: 10.1016/j.pharmthera.2020.107503. Epub 2020 Feb 14. PMID: 32061923; PMCID: PMC7102585.

19. Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014 May;68(5):557-67. doi: 10.1111/ijcp.12361. Epub 2014 Feb 6. PMID: 24499291; PMCID: PMC4238422.
20. Tchang BG, Aras M, Kumar RB, et al. Pharmacologic Treatment of Overweight and Obesity in Adults. [Updated 2024 Aug 20]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279038/
21. Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. *BMJ Open Sport Exerc Med*. 2017;2(1):e000143. doi:10.1136/bmjsem-2016-000143
22. Mikus CR, Oberlin DJ, Libla JL, et al. Lowering physical activity impairs glycemic control in healthy volunteers. *Med Sci Sports Exerc*. 2012;44(2):225–231. doi:10.1249/MSS.0b013e31822dcd4f
23. Way KL, Hackett DA, Baker MK, Johnson NA. The effect of regular aerobic exercise on blood lipids in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. *Clin Obes*. 2016;6(2):73–81. doi:10.1111/cob.12128
24. Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. *BMJ Open Sport Exerc Med*. 2017;2(1):e000143. doi:10.1136/bmjsem-2016-000143
25. Holten MK, Zacho M, Gaster M, et al. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. *Diabetes*. 2004;53(2):294–305. doi:10.2337/diabetes.53.2.294. Diabetes Journals+2Harvard Dash+2BioMed Central+2
26. Ibañez J, Izquierdo M, Argüelles I, et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. *Diabetes Care*. 2005;28(3):662–667. doi:10.2337/diacare.28.3.662.
27. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2011;305(17):1790–1799. doi:10.1001/jama.2011.576.
28. The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. *Arch Intern Med*. 2010;170(17):1566–1575. doi:10.1001/archinternmed.2010.334.
29. Zhao X, He Q, Zeng Y, Cheng L. Effectiveness of combined exercise in people with type 2 diabetes and concurrent overweight/obesity: a systematic review and meta-analysis. *BMJ Open*. 2021;11(10):e046252. doi:10.1136/bmjopen-2020-046252.
30. Boulé NG, Haddad E, Kenny GP, et al. Effects of exercise training on glycemic control and body mass in type 2 diabetes mellitus. *Diabetes Care*. 2001;24(6):1085–1094. doi:10.2337/diacare.24.6.1085.
31. GRADE Study. A comparison of strategies for managing type 2 diabetes: The GRADE study. *JAMA*. 2018;320(8):746–760. doi:10.1001/jama.2018.11163.
32. The VERIFY Study Group. The effect of liraglutide and exercise on insulin sensitivity and cardiovascular risk factors. *Diabetes Care*. 2020;43(7):1472–1481. doi:10.2337/dc19-1823.